Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice

Julio E. Ayala, Deanna P. Bracy, Brianna M. Julien, Jeffrey N. Rottman, Patrick T. Fueger, David H. Wasserman

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

Stimulation of nitric oxide-cGMP signaling results in vascular relaxation and increased muscle glucose uptake. We show that chronically inhibiting cGMP hydrolysis with the phosphodiesterase-5 inhibitor sildenafil improves energy balance and enhances in vivo insulin action in a mouse model of diet-induced insulin resistance. High-fat-fed mice treated with sildenafil plus L-arginine or sildenafil alone for 12 weeks had reduced weight and fat mass due to increased energy expenditure. However, uncoupling protein-1 levels were not increased in sildenafil-treated mice. Chronic treatment with sildenafil plus L-arginine or sildenafil alone increased arterial cGMP levels but did not adversely affect blood pressure or cardiac morphology. Sildenafil treatment, with or without L-arginine, resulted in lower fasting insulin and glucose levels and enhanced rates of glucose infusion, disappearance, and muscle glucose uptake during a hyperinsulinemic (4 mU·kg-1·min-1)- euglycemic clamp in conscious mice. These effects occurred without an increase in activation of muscle insulin signaling. An acute treatment of high fat-fed mice with sildenafil plus L-arginine did not improve insulin action. These results show that phosphodiesterase-5 is a potential target for therapies aimed at preventing diet-induced energy imbalance and insulin resistance.

Original languageEnglish (US)
Pages (from-to)1025-1033
Number of pages9
JournalDiabetes
Volume56
Issue number4
DOIs
StatePublished - Apr 2007
Externally publishedYes

Fingerprint

Fats
Insulin
Arginine
Glucose
Insulin Resistance
Type 5 Cyclic Nucleotide Phosphodiesterases
Diet
Phosphodiesterase 5 Inhibitors
Muscles
Muscle Relaxation
Glucose Clamp Technique
Sildenafil Citrate
Energy Metabolism
Blood Vessels
Fasting
Nitric Oxide
Hydrolysis
Blood Pressure
Weights and Measures

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Ayala, J. E., Bracy, D. P., Julien, B. M., Rottman, J. N., Fueger, P. T., & Wasserman, D. H. (2007). Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes, 56(4), 1025-1033. https://doi.org/10.2337/db06-0883

Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. / Ayala, Julio E.; Bracy, Deanna P.; Julien, Brianna M.; Rottman, Jeffrey N.; Fueger, Patrick T.; Wasserman, David H.

In: Diabetes, Vol. 56, No. 4, 04.2007, p. 1025-1033.

Research output: Contribution to journalArticle

Ayala, JE, Bracy, DP, Julien, BM, Rottman, JN, Fueger, PT & Wasserman, DH 2007, 'Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice', Diabetes, vol. 56, no. 4, pp. 1025-1033. https://doi.org/10.2337/db06-0883
Ayala, Julio E. ; Bracy, Deanna P. ; Julien, Brianna M. ; Rottman, Jeffrey N. ; Fueger, Patrick T. ; Wasserman, David H. / Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. In: Diabetes. 2007 ; Vol. 56, No. 4. pp. 1025-1033.
@article{e722537e4fbf46e2bcad31c960d09527,
title = "Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice",
abstract = "Stimulation of nitric oxide-cGMP signaling results in vascular relaxation and increased muscle glucose uptake. We show that chronically inhibiting cGMP hydrolysis with the phosphodiesterase-5 inhibitor sildenafil improves energy balance and enhances in vivo insulin action in a mouse model of diet-induced insulin resistance. High-fat-fed mice treated with sildenafil plus L-arginine or sildenafil alone for 12 weeks had reduced weight and fat mass due to increased energy expenditure. However, uncoupling protein-1 levels were not increased in sildenafil-treated mice. Chronic treatment with sildenafil plus L-arginine or sildenafil alone increased arterial cGMP levels but did not adversely affect blood pressure or cardiac morphology. Sildenafil treatment, with or without L-arginine, resulted in lower fasting insulin and glucose levels and enhanced rates of glucose infusion, disappearance, and muscle glucose uptake during a hyperinsulinemic (4 mU·kg-1·min-1)- euglycemic clamp in conscious mice. These effects occurred without an increase in activation of muscle insulin signaling. An acute treatment of high fat-fed mice with sildenafil plus L-arginine did not improve insulin action. These results show that phosphodiesterase-5 is a potential target for therapies aimed at preventing diet-induced energy imbalance and insulin resistance.",
author = "Ayala, {Julio E.} and Bracy, {Deanna P.} and Julien, {Brianna M.} and Rottman, {Jeffrey N.} and Fueger, {Patrick T.} and Wasserman, {David H.}",
year = "2007",
month = "4",
doi = "10.2337/db06-0883",
language = "English (US)",
volume = "56",
pages = "1025--1033",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "4",

}

TY - JOUR

T1 - Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice

AU - Ayala, Julio E.

AU - Bracy, Deanna P.

AU - Julien, Brianna M.

AU - Rottman, Jeffrey N.

AU - Fueger, Patrick T.

AU - Wasserman, David H.

PY - 2007/4

Y1 - 2007/4

N2 - Stimulation of nitric oxide-cGMP signaling results in vascular relaxation and increased muscle glucose uptake. We show that chronically inhibiting cGMP hydrolysis with the phosphodiesterase-5 inhibitor sildenafil improves energy balance and enhances in vivo insulin action in a mouse model of diet-induced insulin resistance. High-fat-fed mice treated with sildenafil plus L-arginine or sildenafil alone for 12 weeks had reduced weight and fat mass due to increased energy expenditure. However, uncoupling protein-1 levels were not increased in sildenafil-treated mice. Chronic treatment with sildenafil plus L-arginine or sildenafil alone increased arterial cGMP levels but did not adversely affect blood pressure or cardiac morphology. Sildenafil treatment, with or without L-arginine, resulted in lower fasting insulin and glucose levels and enhanced rates of glucose infusion, disappearance, and muscle glucose uptake during a hyperinsulinemic (4 mU·kg-1·min-1)- euglycemic clamp in conscious mice. These effects occurred without an increase in activation of muscle insulin signaling. An acute treatment of high fat-fed mice with sildenafil plus L-arginine did not improve insulin action. These results show that phosphodiesterase-5 is a potential target for therapies aimed at preventing diet-induced energy imbalance and insulin resistance.

AB - Stimulation of nitric oxide-cGMP signaling results in vascular relaxation and increased muscle glucose uptake. We show that chronically inhibiting cGMP hydrolysis with the phosphodiesterase-5 inhibitor sildenafil improves energy balance and enhances in vivo insulin action in a mouse model of diet-induced insulin resistance. High-fat-fed mice treated with sildenafil plus L-arginine or sildenafil alone for 12 weeks had reduced weight and fat mass due to increased energy expenditure. However, uncoupling protein-1 levels were not increased in sildenafil-treated mice. Chronic treatment with sildenafil plus L-arginine or sildenafil alone increased arterial cGMP levels but did not adversely affect blood pressure or cardiac morphology. Sildenafil treatment, with or without L-arginine, resulted in lower fasting insulin and glucose levels and enhanced rates of glucose infusion, disappearance, and muscle glucose uptake during a hyperinsulinemic (4 mU·kg-1·min-1)- euglycemic clamp in conscious mice. These effects occurred without an increase in activation of muscle insulin signaling. An acute treatment of high fat-fed mice with sildenafil plus L-arginine did not improve insulin action. These results show that phosphodiesterase-5 is a potential target for therapies aimed at preventing diet-induced energy imbalance and insulin resistance.

UR - http://www.scopus.com/inward/record.url?scp=34047094881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047094881&partnerID=8YFLogxK

U2 - 10.2337/db06-0883

DO - 10.2337/db06-0883

M3 - Article

VL - 56

SP - 1025

EP - 1033

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 4

ER -